What is a fair fractional CRO equity grant in 2027?

Building the grant from scope, not from a number

The mistake almost every founder makes is starting with a percentage. Someone says "1%" in a first call, both sides anchor to it, and the rest of the negotiation becomes a tug-of-war over a figure neither party derived from anything. The disciplined path runs the other direction: define the scope, convert scope into days, convert days into an annual cash-equivalent value, then decide how much of that value you are paying in equity instead of cash. The percentage falls out of that arithmetic. It is the output, not the input.

Start with what the fractional Chief Revenue Officer will actually own. There is a real difference between "build our first repeatable sales motion from zero" and "fix our forecast accuracy and coach the two AEs we already have." The first is a founding-team-shaped mandate: pricing, ICP definition, the first playbook, the first two or three hires, the CRM and RevOps foundation, and probably the sales narrative that goes into the next fundraise deck. The second is a bounded project with a definable end. Those two engagements can involve the same number of days per month and still justify a 4x difference in equity, because one creates durable enterprise value that persists after the engagement ends and the other improves an operating metric while the engagement runs.

Then convert to days. A fractional CRO engagement in 2027 typically runs somewhere between 4 and 20 days per month. Below about 4 days, you are buying advisory time, not leadership, and the appropriate instrument is an advisor grant on a standard advisor schedule — 0.1% to 0.5%, two-year vest, no cliff or a short one. Above about 15 days a month, you are approaching three-quarters of a full-time executive and the grant should approach a meaningful fraction of a full-time grant. The middle of that band, roughly 8 to 12 days, is where the majority of engagements sit and where the negotiation actually gets interesting.

The last conversion step is the one people skip. Take the days per month, multiply by twelve, and ask: what would this person's time cost at their prevailing market rate if you paid entirely in cash? Now compare that number to the cash you are actually offering. The gap is what the equity is buying. If you are paying 60% of the cash-equivalent value, the equity needs to be worth substantially more than the missing 40% at a realistic outcome, because the executive is taking illiquidity risk, dilution risk, and outcome risk on that portion. Equity that merely matches the cash you did not pay is not compensation for risk; it is a deferred invoice with a chance of never being paid.

This is also where the internal fairness check happens. Run the same arithmetic against your existing team. If your first sales hire has 0.4% for full-time work over four years, granting your fractional CRO 2.5% for ten days a month is going to be a problem the moment anyone compares notes, and someone always compares notes. Fairness inside the cap table matters as much as fairness against the external market, and it is the one your team can actually observe.

The end-to-end process from first call to signed grant

The sequence below is what a clean engagement looks like from the founder's side. It takes two to four weeks to run properly, and rushing it is the single most reliable predictor of a grant both sides resent within six months.

Scope conversation (week one). Write down the three to five outcomes the engagement exists to produce. Be specific enough that a neutral third party could judge whether they happened. "Improve sales" fails that test. "Ship a documented discovery-to-close playbook, hire and onboard two AEs, and get forecast variance under 15% by quarter end" passes it. This document does more work than any other artifact in the process, because it is what you will point to during vesting disputes, scope creep arguments, and the eventual conversation about whether to convert to full-time.

Time and cadence definition. Days per month, but also the shape of those days. A CRO who can give you four consecutive days a month is useful for build work and useless for deal support. One who gives you two half-days a week is the reverse. Write down which meetings they own — pipeline review, forecast call, board prep — because those recurring commitments are the real time floor and they tend to grow.

Cash offer first, equity second. Establish the retainer before discussing percentages. Once you know the cash, the equity conversation has a reference point instead of floating free. Retainers scale with days and seniority; a ten-day-a-month engagement with a genuinely senior operator sits in a different band than a four-day advisory arrangement, and both sides usually know their bands.

409A check. If your most recent 409A valuation is more than twelve months old, or if you have had a material event since — a priced round, a large customer win, a pivot — get it refreshed before granting. Granting options at a stale strike price is a tax problem for the recipient and a compliance problem for you. This is not optional paperwork; a below-FMV strike on an NSO can trigger 409A penalties for the executive, and they will find out about it at exactly the worst time.

Board or shareholder approval. Option grants require board approval, and your equity incentive plan has a pool with a finite balance. Check the remaining pool before you promise anything. Founders routinely discover mid-negotiation that the pool has 0.8% left and they have verbally offered 1.5%, which means either a pool expansion — dilutive to everyone including the founders — or an awkward retraction.

Documentation. The grant agreement, the engagement agreement, and the scope document should reference each other. Milestone-based vesting in particular has to be written with the milestones defined in enough detail that a lawyer reading it cold could adjudicate. "Hit the revenue plan" is not adjudicable. "$2.4M in recognized ARR as reported in the audited statements for the fiscal year" is.

Where the grant creates value and where it leaks

Equity is not a discount mechanism. When it functions correctly, it changes what the fractional executive does on a Tuesday afternoon when nobody is watching — and that behavioral shift is the entire return on the grant. When it functions incorrectly, you have permanently given away part of the company in exchange for effort you would have received anyway.

The clearest place it creates value is in decisions with a long payback. A cash-only fractional CRO has a rational incentive toward visible wins inside the engagement window: close the deals in the pipeline, run the sales training, produce the dashboard. All useful. But the highest-value work in a young revenue organization is often invisible for two or three quarters — rebuilding the ICP so the pipeline stops filling with deals that churn, killing a channel that produces volume and no margin, telling the founder that the first sales hire was the wrong hire. An operator with real equity is more willing to spend their political capital on those conversations, because they own the downstream consequence. This is the single strongest argument for granting meaningfully rather than minimally.

It also creates value in referral and network flow. A fractional CRO with a real stake introduces you to candidates, customers, and investors from their network in a way that a purely transactional relationship rarely produces at the same intensity. That flow is hard to measure and easy to underestimate, and it is one of the reasons the equity-heavy structure survives despite its cap table cost.

The leaks are more numerous. The first is the dead grant: equity that vests on a calendar while the engagement drifts. Six months in, the executive is doing two days a month instead of ten, nobody has renegotiated, and 12.5% of a 2% grant has vested for a fraction of the promised work. The fix is structural — tie some portion of vesting to the engagement's actual delivery, and build a scheduled scope review into the agreement rather than relying on someone to raise the awkward topic.

The second leak is cap table congestion. Three fractional executives at 1% each, plus four advisors at 0.25%, plus a departed cofounder, and suddenly you are carrying 5% in non-employee equity into a Series A conversation. Investors notice. They will not necessarily kill the deal over it, but they will price it, and the pricing usually comes out of the founders' side of the table. Model the aggregate before granting the third one, not after.

The third and subtlest leak is misalignment between the grant's time horizon and the engagement's. A four-year vest on a nine-month engagement is a structure that guarantees an unresolved conversation. Either the executive leaves with 25% vested and a residual claim on a company they no longer help, or you negotiate an early exit under time pressure. Match the vesting term to the realistic engagement horizon, and if you genuinely do not know that horizon, use a shorter vest with an explicit extension mechanism rather than a long one you hope to unwind.

There is also a downstream effect worth naming: what happens when the fractional CRO's work succeeds and you hire a full-time CRO. The incoming full-time executive will want a grant sized against the current valuation, which the fractional CRO helped create. If the fractional grant is oversized, that new hire's package becomes harder to fund from the remaining pool, and you end up paying for the same function twice. Plan the succession into the grant — a defined transition role, or vesting that concludes at the handoff — rather than discovering the conflict during the full-time search.

Concrete numbers and benchmark ranges

The following bands reflect where the fractional market has generally settled, though the spread within any band is wide and driven by the specifics above. Treat them as a starting range to reason from, not as quotable market data — this is a market without reliable public survey coverage, and anyone claiming precise percentile data is extrapolating.

Pre-revenue through roughly $500K ARR. Equity in the 1.5% to 3.0% range for a genuine 10-to-15-day-per-month founding revenue mandate. Cash is typically well below market rate, sometimes as low as a nominal retainer, because the company cannot fund more. The executive is underwriting real risk: no product-market fit proof, no revenue base, and a meaningful chance the company does not exist in eighteen months. At the top of this band you are essentially bringing on a part-time founding executive, and the grant should be structured like one — four-year vest, one-year cliff, and a serious conversation about whether the role converts to full-time if the thesis works.

Roughly $1M to $5M ARR. Equity in the 0.25% to 1.0% range for a similar day commitment, with cash rising substantially toward market. Risk has fallen; there is a revenue base, some evidence of repeatability, and usually institutional money on the cap table. The mandate shifts from creation to optimization — conversion rate improvement, forecast discipline, quota and territory design, first sales manager hire, and the RevOps instrumentation that makes any of it measurable. The equity should still be worth something meaningful at a plausible outcome. Do the multiplication before you offer: 0.3% of a company that might exit at $60M is roughly $180K pre-dilution and pre-tax, spread over four years of vesting. That is real. 0.1% of a company that might exit at $20M is $20K, which will not change anyone's behavior and should not be dressed up as though it will.

Above roughly $5M ARR. Equity in the 0.1% to 0.5% range, frequently on a shorter two-to-three-year vest, with cash as the dominant component. At this stage the fractional engagement is usually project-shaped: enter a new segment, rebuild a broken channel, bridge the gap while the full-time CRO search runs. Interim CRO engagements — full-time hours, defined duration — are a distinct structure and often use cash plus a completion bonus rather than equity at all, because a six-month interim does not fit a four-year vest.

Cash-to-equity spectrum. Across all stages, three structures recur. Cash-heavy with light equity, typically 0.1% to 0.3%, suits executives with a full client roster who value liquidity over lottery tickets. Balanced, roughly 0.5% to 1.5%, is the most common growth-stage shape. Equity-heavy with thin cash, 2.0% to 3.0%, works when the founder needs senior depth and genuinely cannot pay for it — but only when the founder is transparent about why, and only when the equity math actually justifies the trade.

Comparison to full-time. A full-time CRO at seed stage might see 3% to 7%; at $2M–$5M ARR, roughly 1.5% to 3.0%. The fractional discount is not proportional to hours — a ten-day-a-month fractional CRO delivering 25% of the hours does not get 25% of the grant, they typically get closer to a third to a half of it, because the strategic leverage per hour is higher and the ramp is faster. A fractional VP of Sales, by contrast, usually sits at 0.1% to 0.5% for comparable time, since the mandate covers sales execution rather than the full revenue engine including marketing, customer success, and RevOps.

Instrument and mechanics. NSOs are the common instrument for fractional roles, since ISOs generally require employee status and carry a $100K-per-year vesting limitation on favorable treatment. Strike price is set at fair market value per the 409A. Standard expiration is ten years from grant, though the post-termination exercise window matters more in practice: the default 90-day window is brutal for someone holding options in an illiquid private company, and extending it to five or ten years post-termination is a negotiable term that costs the company nothing in cash and is worth a great deal to the recipient. LLCs sometimes use profit interest units instead, which carry different tax treatment and require their own documentation — worth exploring with counsel, not worth improvising.

Pitfalls and how to avoid them

Over-granting under time pressure. The founder needs revenue leadership urgently, a strong candidate is available, and 2.5% gets offered to close the gap. Eighteen months later that grant is fully vested against a nine-month engagement, and the Series A lead is asking why. Prevention is mechanical: before offering, model the grant against your realistic dilution path through the next two rounds, and check the offer against your existing employee grants for internal consistency.

Under-granting and losing the operator mid-build. The mirror failure. A 0.1% grant at a $10M valuation is $10K of paper value against a multi-year illiquidity horizon — it is not compensation, it is a gesture. Senior operators recognize this instantly, and the ones who accept it anyway are often the ones with the least leverage elsewhere. If you cannot grant meaningfully, pay more cash or build a performance bonus tied to a defined ARR threshold, and say plainly that equity is not the lever here. That honesty preserves the relationship; pretending a token grant is real does not.

Vesting on a calendar the engagement does not share. Covered above, but the specific remedy deserves repeating: consider splitting the grant. Half on standard time-based vesting, half on defined milestones tied to the scope document. Time-based vesting alone rewards presence; milestone vesting alone creates perverse incentives around milestone definition. The split hedges both.

Ignoring acceleration terms until termination. Single-trigger acceleration on termination without cause is a reasonable ask and common in fractional agreements, since the executive has less protection than an employee. Double-trigger acceleration on change of control plus termination is the standard corporate structure and is worth understanding before you agree to it — a full single-trigger acceleration on change of control can create acquisition friction, because the acquirer sees vested equity walking out the door and prices accordingly. Negotiate these at signing when the relationship is warm, not at exit when it is not.

Skipping the 409A. Granting at a stale or absent valuation is the pitfall with actual legal teeth. A discounted strike price on an NSO can trigger immediate income recognition plus a 20% additional tax under Section 409A for the recipient. Refresh the valuation before granting after any material event. The cost of a 409A is trivial compared to the cost of unwinding a mispriced grant.

Confusing fractional with interim. They are different products with different compensation logic. Fractional is ongoing and part-time; interim is full-time and temporary. Applying a four-year vest to a six-month interim engagement produces a structure that serves nobody. Interim engagements are better served by higher cash plus a completion or performance bonus.

No exit mechanism for the shares. When the engagement ends, the former fractional CRO holds illiquid shares or options in your private company indefinitely, and shows up on every cap table page for the next decade. A right of first refusal and a company repurchase option at fair market value for unexercised or recently exercised shares is standard and worth including from the start. Adding it later requires the holder's consent, which is a much harder conversation.

Letting scope creep untracked. The fractional CRO who was hired for ten days a month is now on four weekly calls, the board deck, and every enterprise deal review. Either compensate for the expanded scope or hold the line on it, but do not let it drift silently — that is how good engagements curdle. A quarterly scope review written into the agreement makes the conversation routine rather than confrontational.

A selection checklist before you sign

Run these checks in order. Any one of them failing is a signal to slow down rather than a reason to walk away, but two or more failing usually means the deal is not ready.

Does the scope document name three to five outcomes a neutral party could judge? Does the day commitment match the scope honestly — not the number that makes the budget work, the number the work actually requires? Is the cash offer inside a defensible band for the seniority you are buying? Does the equity grant, multiplied against a plausible exit valuation and discounted for dilution, produce a number that would change this specific person's behavior? Is the option pool large enough to fund this grant plus the next two hires you know are coming? Is the 409A current? Does the vesting term match the realistic engagement horizon, and if not, is there an explicit mechanism to resolve the mismatch? Are acceleration, repurchase rights, and the post-termination exercise window all written down? And finally — is there a defined path for what happens when this works, whether that is conversion to full-time, transition to a hired CRO, or a clean wind-down?

One more check that sits outside the paperwork: does this person want the equity, or are they accepting it? An operator who negotiates hard on equity terms is usually one who intends to be around for the outcome. One who waves the equity conversation away and focuses entirely on the retainer is telling you something about how they see the engagement, and it is worth hearing.

What the grant looks like from the operator's side

Founders negotiate one of these at a time. A working fractional CRO negotiates several a year, and understanding how they evaluate an offer makes the negotiation faster and the outcome better for both parties.

The operator is building a portfolio, and portfolios have concentration limits. Someone carrying four clients cannot take equity-heavy, cash-light terms on all four — they need enough cash flow to fund a household while the equity matures. This means the same executive may accept 0.3% and a strong retainer from one client and 2.5% and a thin retainer from another, and neither number tells you anything about how they value your company. It tells you where that engagement sits in their portfolio's risk balance. Asking directly — "where does this sit for you, cash or upside?" — is a more productive opening than guessing.

They are also evaluating your exit probability, not just your current valuation. A 1% grant at a company with a credible path to a $100M outcome and a 1% grant at a company likely to top out at $15M are wildly different instruments carrying the same label. Experienced operators discount aggressively for outcome uncertainty, which is why the same percentage lands differently depending on how convincing your growth story is. The corollary: the best way to reduce the equity you need to grant is to make the outcome more credible, not to argue about the number.

Exercise cost is a real constraint that founders systematically underestimate. Options are not free to convert. If the strike price has risen and the grant is large, exercising can require a five- or six-figure cash outlay with an AMT bill attached and no liquidity in sight. This is why the post-termination exercise window matters so much, and why some operators prefer restricted stock with an 83(b) election at a low early valuation over options at a higher one. If you are granting at a very early stage, restricted stock is worth discussing — it is cleaner for the recipient and costs you nothing extra.

Finally, they are reading the terms as a signal about you. A founder who has a current 409A, a clean pool, a written scope, and a lawyer who returns calls is signaling operational competence. One who improvises the grant over three weeks of email is signaling something else, and experienced operators price that signal into everything else about the engagement. The grant negotiation is often the first real look either party gets at how the other one operates under mild pressure, and both sides know it.

Related questions

How does a fractional CRO grant compare to a standard advisor grant?

Advisor grants typically run 0.1% to 0.5% on a two-year vest with no cliff or a short one, for a few hours monthly. A fractional CRO at ten-plus days a month carries operating accountability, so the grant is several times larger and follows employee-style vesting with a one-year cliff.

Should equity vest on time or on milestones?

Split it. Time-based vesting rewards continuity and is simple to administer; milestone vesting ties value creation to the grant but requires milestones precise enough to adjudicate. A common structure is half on a standard four-year schedule and half across two or three defined revenue or hiring milestones.

What happens to the equity if the engagement ends after six months?

Nothing vests if the one-year cliff has not passed, which is exactly what the cliff exists to handle. Past the cliff, vested shares remain the executive's subject to the post-termination exercise window and any repurchase rights. Unvested shares return to the pool.

Does a fractional CRO get equity at a bootstrapped, non-venture company?

Sometimes, but the instrument usually changes. Without an exit path, options are close to worthless as motivation. Profit interests in an LLC, phantom equity, or a revenue-share bonus align better, since they pay from operations rather than from a liquidity event that may never come.

How much does the grant change if the CRO is also raising the round?

Materially. Fundraise support — deck narrative, revenue model defense, investor diligence calls — is high-leverage work with direct valuation impact, and it commonly pushes the grant toward the top of the stage band or adds a milestone tranche tied to a completed round.

FAQ

What if the fractional CRO asks for more equity than you planned to offer?

Adjust another variable rather than simply conceding or refusing. If they want 2% and you budgeted 1%, the levers are cash, days, and scope. Raising the retainer often closes the gap because it reduces the risk they are carrying. Reducing days from fifteen to ten narrows the mandate proportionally. The goal is a total package both sides can defend, and the percentage is only one input to it.

Should the company keep a repurchase right on the shares?

Yes, and include it from the beginning. A right of first refusal plus a company repurchase option at fair market value keeps the cap table clean when engagements end, and prevents a former fractional executive from holding illiquid shares in your company indefinitely. Adding these terms after the grant requires the holder's consent, which is a substantially harder conversation than including them at signing.

Is a fair grant different for an interim CRO than a fractional one?

Yes, because the structures differ fundamentally. Interim is full-time and time-boxed — often three to nine months covering a gap. That does not fit a four-year vest. Interim engagements are typically compensated with a higher cash rate plus a completion or performance bonus, with equity either absent or a small grant on an accelerated schedule matched to the engagement length.

How does the grant interact with hiring a full-time CRO later?

Plan for it explicitly. If the fractional engagement succeeds, you will eventually want a full-time revenue leader whose grant is sized against the higher valuation the fractional work helped create. Define the transition in advance — whether the fractional CRO converts, advises through the handoff, or winds down — so the two grants do not compete for the same shrinking option pool.

Can equity be granted in something other than stock options?

Yes. LLCs commonly use profit interest units, which can carry favorable tax treatment but require careful documentation and a threshold value at issuance. Early-stage corporations sometimes use restricted stock with an 83(b) election, which is cleaner for the recipient when the valuation is still low. Phantom equity and revenue-share structures fit companies without a realistic exit path. All of these need counsel.

How does RevOps maturity affect what the grant should be?

Substantially. A company with no CRM hygiene, no pipeline definitions, and no reporting requires the CRO to build the RevOps foundation before any revenue strategy can be measured — months of unglamorous work that expands scope and justifies a larger grant. A company with clean data and functioning RevOps lets the executive start on strategy immediately, which narrows the mandate and the grant alongside it.

Sources

• Section 409A information — Internal Revenue Service
• Harvard Business Review — executive compensation and incentive research
• First Round Review — startup equity and hiring guides
• SaaStr — SaaS hiring, compensation, and fundraising benchmarks
• Y Combinator Library — startup equity and hiring resources
• National Venture Capital Association — model legal documents
• Pavilion — community and resources for revenue leaders
• RevOps Co-op — revenue operations practices and community
• Cooley GO — startup legal and equity documentation resources

Related on PULSE

• What should an SMB company look for in a fractional CRO in 2027?
• Is there a fractional CRO available near me in Boise in 2027?
• Who is the best fractional Chief Revenue Officer in Middletown in 2027?
• Is there a fractional CRO available near me in Pasadena in 2027?
• Is there a fractional CRO available near me in Massachusetts in 2027?
• Is there a fractional Chief Revenue Officer available near me in Detroit in 2027?